E

    Exagen Inc (XGN)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $7.34
    -0.05 (-0.68%)

    Market Cap: $177.81M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    79%(22/28)
    Avg Surprise
    -0.65%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.17
    Range$-0.17 - $-0.16
    2 analysts
    EPS RevisionsNo revisions (7d)
    0
    2
    30d
    EPS Estimate Drift
    90d ago$-0.17-3.0%
    60d ago$-0.14+12.1%
    30d ago$-0.14+12.1%
    7d ago$-0.15+9.1%
    Current$-0.17
    Revenue Consensus
    $18M
    Range$18M - $19M
    7 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.04
    Range$-0.04 - $-0.03
    2 analysts
    Revenue Consensus
    $21M
    Range$21M - $22M
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.04---
    Sep 26EST
    		-$-0.17---
    Jun 26
    Reported Aug 4
    		$-0.13$-0.19+31.58%Beat+27.8%
    Mar 26
    Reported May 11
    		$-0.20$-0.25+20.00%Beat+0.0%
    Dec 25
    Reported Mar 10
    		$-0.27$-0.18-48.80%Miss-33.1%
    Sep 25
    Reported Nov 4
    		$-0.31$-0.16-93.75%Miss-10.7%
    Jun 25
    Reported Jul 29
    		$-0.18$-0.15-20.00%Miss-12.5%
    Mar 25
    Reported May 5
    		$-0.20$-0.21+4.76%Beat-5.3%
    Dec 24
    Reported Mar 11
    		$-0.20$-0.24+16.67%Beat+35.5%
    Sep 24
    Reported Nov 12
    		$-0.28$-0.28+0.00%Beat+9.7%
    Jun 24
    Reported Aug 5
    		$-0.16N/A+54.29%Beat+42.9%
    Mar 24
    Reported May 13
    		$-0.19$-0.35+45.71%Beat+56.8%
    Dec 23
    Reported Mar 18
    		$-0.31$-0.43+27.91%Beat+62.7%
    Sep 23
    Reported Nov 13
    		$-0.31$-0.49+36.73%Beat+34.0%
    Jun 23
    Reported Aug 7
    		$-0.28$-0.49+42.86%Beat+64.1%
    Mar 23
    Reported May 15
    		$-0.44$-0.56+21.43%Beat+26.7%
    Dec 22
    Reported Mar 20
    		$-0.83$-0.78-6.41%Miss-97.6%
    Sep 22
    Reported Nov 14
    		$-0.47$-0.76+38.16%Beat-11.9%
    Jun 22
    Reported Aug 4
    		$-0.78$-0.57-36.84%Miss-105.3%
    Mar 22
    Reported May 11
    		$-0.60$-0.61+1.64%Beat-25.0%
    Dec 21
    Reported Mar 22
    		$-0.42$-0.50+16.00%Beat-55.6%
    Sep 21
    Reported Nov 10
    		$-0.42$-0.47+10.64%Beat-23.5%
    Jun 21
    Reported Aug 9
    		$-0.38$-0.44+13.64%Beat-40.7%
    Mar 21
    Reported May 11
    		$-0.48$-0.48+0.00%Beat-9.1%
    Dec 20
    Reported Mar 16
    		$-0.27$-0.41+34.15%Beat+0.0%
    Sep 20
    Reported Nov 10
    		$-0.34$-0.47+27.66%Beat+97.0%
    Jun 20
    Reported Jul 28
    		$-0.27N/A+65.82%Beat+83.1%
    Mar 20
    Reported May 11
    		$-0.44$-0.56+21.43%Beat-
    Dec 19
    Reported Mar 25
    		$-0.27$-0.37+27.03%Beat-
    Sep 19
    Reported Nov 12
    		$-11.29$-2.40-370.42%Miss-
    Jun 19
    Reported Sep 20
    		$-1.60$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-8.10EV/EBITDA-0.16x
    Price/FCF-23.37xFCF Yield-4.28%
    Profitability
    Profit Margin-26.60%Operating Margin-8.64%
    ROE-113.80%ROIC-43.94%
    Financial Health
    Debt/Equity1.87xInterest Coverage-3.01x
    Current Ratio3.18xQuick Ratio3.18x
    Trading Statistics
    Beta2.03Avg Volume480.47K
    52-Week High$12.2352-Week Low$2.59

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$7.49
    SMA 20$7.07
    SMA 50$5.55
    SMA 200$4.81
    EMA 10$7.35
    EMA 20$6.91
    EMA 50$5.91
    EMA 200$5.28

    MACD

    Line: 0.62Signal: 0.66Hist: -0.04

    ADX

    ADX: 49.1+DI: 27.3-DI: 14.7

    Aroon & PSAR

    Aroon Up76.0
    Aroon Down4.0
    PSAR$6.66

    Bollinger Bands

    Upper Band$8.08
    Lower Band$6.06
    %B Position2851%(Upper)
    Band Width0.63

    RSI (14-Day)

    Neutral
    64.0

    Momentum Oscillators

    Stoch %K61.7
    Stoch %D68.2
    Williams %R-43.4
    ROC (10d)9.6%
    Momentum0.64
    CCI (20d)29.4
    MFI (14d)48.9

    Volatility Measures

    ATR (14d)$0.43(5.8%)
    StdDev (20d)0.50
    Hist Vol143.8%(High)

    Volume Flow

    VWAP$7.26
    OBV5.8M
    AD Line387.7K
    CMF (20d)0.104

    Volume Metrics

    Avg Vol (20d)493.9K
    Vol Ratio0.7x
    VWMA (20d)$6.87

    Pivot Points

    R3$8.15
    R2$7.96
    R1$7.68
    Pivot Point$7.49
    S1$7.21
    S2$7.02
    S3$6.74

    Advanced Oscillators

    TSI39.38
    Ultimate Osc47.8
    KST522.23

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$19.94M$17.31M$16.63M$17.24M$17.20M$15.50M$13.65M$12.51M$15.06M$14.41M$13.77M$13.42M
    Cost of Revenue$7.72M$7.10M$7.42M$7.17M$6.81M$6.38M$5.18M$5.53M$6.01M$5.82M$5.62M$5.71M
    Gross Profit$12.22M$10.21M$9.21M$10.07M$10.39M$9.12M$8.48M$6.98M$9.06M$8.60M$8.14M$7.71M
    Operating Expenses$13.94M$13.62M$14.18M$13.18M$13.03M$12.49M$11.86M$11.64M$11.64M$11.60M$13.29M$12.78M
    R&D$1.43M$1.55M$1.76M$1.73M$1.48M$1.28M$1.66M$1.48M$1.18M$1.06M$1.08M$1.40M
    SG&A$12.51M$12.07M$12.42M$11.45M$11.54M$11.20M$10.20M$10.16M$10.46M$10.54M$12.22M$11.38M
    Operating Income$-1,722,000$-3,414,000$-4,975,000$-3,100,000$-2,630,000$-3,365,000$-3,383,000$-4,663,000$-2,587,000$-3,003,000$-5,147,000$-5,069,000
    Interest Income$0$0$43,000$3,000$0$0$197,000$197,000$181,000$192,000$173,000$211,000
    Interest Expense$1.20M$1.27M$1.33M$1.32M$1.42M$545,000$563,000$562,000$560,000$549,000$566,000$557,000
    Income Before Tax$-3,196,000$-3,931,000$-4,660,000$-7,086,000$-4,402,000$-3,752,000$-3,749,000$-5,028,000$-2,966,000$-3,360,000$-5,540,000$-5,415,000
    Income Tax Expense$0$36,000$0$1,000$37,000$0$0$0$0$0$0$0
    Net Income$-3,196,000$-3,967,000$-4,673,000$-7,087,000$-4,439,000$-3,752,000$-3,761,000$-5,028,000$-2,966,000$-3,360,000$-5,573,000$-5,415,000
    EBITDA$-1,048,000$-1,271,000$-3,967,000$-4,571,000$-2,254,000$-2,725,000$-2,926,000$-4,207,000$-2,117,000$-2,508,000$-4,603,000$-4,425,000
    EBIT$-1,995,000$-2,664,000$-4,975,000$-5,770,000$-2,983,000$-3,207,000$-3,383,000$-4,663,000$-2,587,000$-3,003,000$-5,147,000$-5,069,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about XGN

    News

    Exagen (XGN) director grant corrects prior option total

    Exagen Inc. (XGN) director Bruce C. Robertson filed an amended Form 4 to correct a prior report regarding his stock option holdings. The amendment clarifies that he was granted and beneficially owns 37,500 stock options with an exercise price of $4.31 per share, not the previously overstated 55,000 options. These options, exercisable for 37,500 shares, will fully vest on the earlier of the first anniversary of the June 9, 2026 grant date or the next annual stockholders' meeting, contingent on his continued board service.

    Stock Titan•8/24/26•
    Neutral

    Exagen (NASDAQ: XGN) grants Paul Kim 37,500 options at $4.31

    Exagen Inc. (NASDAQ: XGN) director Paul Kim was granted 37,500 stock options to purchase common stock at an exercise price of $4.31 per share. These options, expiring on 2036-06-08, vest fully on the earlier of the first anniversary of the grant date or the next annual meeting, conditional on his continued board service. Following this transaction, Kim directly holds 46,500 stock options.

    Stock Titan•8/19/26•
    Neutral

    Exagen (NASDAQ: XGN) grants director options at $4.31 strike

    EXAGEN INC. (XGN) director Bruce C. Robertson was granted 37,500 stock options at an exercise price of $4.31 per share on June 9, 2026. These options vest on the earlier of the first anniversary of the grant date or the next annual stockholders' meeting, contingent on his continued board service, and expire on June 8, 2036. Following this grant, Robertson directly holds options for 55,500 shares.

    Stock Titan•8/19/26•
    Neutral

    GSA Capital Partners LLP Makes New Investment in Exagen Inc. $XGN

    GSA Capital Partners LLP has acquired a new stake of 214,721 shares in Exagen Inc. (NASDAQ:XGN), valued at approximately $998,000, as per its latest 13F filing. Other institutional investors have also adjusted their holdings in the company. Exagen's stock opened at $6.70, with a market capitalization of $162.34 million, and analysts have an average "Moderate Buy" rating with a consensus price target of $9.62.

    MarketBeat•8/18/26•
    Somewhat-Bullish

    Flputnam Investment Management Co. Takes $1.34 Million Position in Exagen Inc. $XGN

    Flputnam Investment Management Co. has acquired a new stake of 288,810 shares in Exagen Inc. (NASDAQ:XGN) valued at approximately $1.34 million during the second quarter, representing about 1.20% of the company. Several other hedge funds have also adjusted their positions in Exagen, and institutional investors collectively own 75.25% of the stock. Analyst ratings for XGN are predominantly positive, with a consensus "Moderate Buy" rating and an average price target of $9.62.

    MarketBeat•8/18/26•
    Somewhat-Bullish

    Frequently Asked Questions About XGN

    Does XGN pay dividends?
    Exagen Inc (XGN) does not currently pay a regular dividend.
    What is XGN's market cap?
    Exagen Inc (XGN) has a market capitalization of $177.81M with a current stock price of $7.34.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In